-
Application of ADC in First-Line Treatment of NSCLC and Interpretation of Results from the EVOKE-02 Study
The 24th World Conference on Lung Cancer (WCLC) was held from September 9 to 12, 2023, in Singapore, organized by the International Association for the Study of Lung Cancer (IASLC). During the oral presentation session on September 10, the EVOKE-02 study, exploring the first-line treatment of advanced non-small cell lung cancer (NSCLC) with the combination…
-
WCLC Live Interview | Dr. Baohui Han and Dr. Roy Herbst Interpret FAVOUR Study, Discuss the Treatment of Advanced Lung Cancer with EGFR ex20ins Mutation
The 24th World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place from September 9th to 12th, 2023, in Singapore.…
-
WCLC Interview | Dr. CaiCun Zhou Interprets Important Researches and Future Trends in the Field of ADC
Editor’s Note: The 2023 World Conference on Lung Cancer (WCLC) was held in Singapore from September 9 to 12. The “Oncology Frontier” team delved into the frontlines, capturing international advancements,…
-
Polatuzumab Vedotin Enhances Treatment Efficacy in Previously Untreated DLBCL: Insights from the Asia Subpopulation of the POLARIX Trial
In an enlightening development within the realm of oncology, a recent study titled “Polatuzumab Vedotin in Previously Untreated DLBCL: An Asia Subpopulation Analysis from the Phase 3 POLARIX Trial” has…
-
Comprehensive Analysis of Orelabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Phase 1/2 Study
Mantle cell lymphoma (MCL) represents a distinct subtype of B-cell non-Hodgkin lymphoma, characterized by its aggressive nature and poor prognosis, particularly in the relapsed or refractory (r/r) setting. The advent…
-
Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study
Marginal zone lymphoma (MZL) is a subtype of non-Hodgkin lymphoma characterized by a slow progression. It originates from B cells in the marginal zone of lymphoid tissues and is associated…
-
Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin lymphoma represents a unique therapeutic challenge, particularly for those with relapsed or refractory disease after first-line therapies. Despite advances in treatment, the prognosis for this subgroup remains suboptimal. Anti-programmed…
-
Unlocking the Cure: A Groundbreaking Study on ENKTCL Treatment Success Rates and Implications
The research on Extranodal nasal-type natural killer/T-cell lymphoma (ENKTCL) has seen significant advancements in recent years, with improved treatment modalities enhancing patient survival rates. The study titled “Evidence of Cure…
Connecting Medical Expertise through Media